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ABSTRACT
Attenuation of Spatial Memory Impairment in a
Tau Mouse Model of Alzheimer’s Disease with Riluzole
Daniel Weitzner
Individuals at risk for developing Alzheimer's disease (AD) often demonstrate
hyperactivity in areas of the memory network, such as the hippocampus, prior to AD diagnosis.
Evidence suggests that this hyperactivity might be a contributing factor to the development of
AD. Tau, a protein responsible for binding and maintaining microtubules, has been implicated as
a factor in hyperactivity, potentially through its alterations in glutamate signaling. Glutamate, the
primary excitatory neurotransmitter in the central nervous system, is essential for learning and
memory. However, excess glutamate that accumulates in the synapse can lead to neuron loss and
eventual behavioral impairments. Recently, our lab has found that a tau mouse model of AD
(rTg(TauP301L)4510) exhibits an increase in glutamate release and a decrease in glutamate
clearance, effects that are correlated with memory deficits. We hypothesized that regulating
glutamate levels would attenuate the spatial memory deficits observed in TauP301L mice. To
test this, we administered riluzole, an FDA-approved disease-modifying drug for the treatment of
amyotrophic lateral sclerosis, which decreases glutamate release and increases glutamate uptake.
TauP301L mice exhibited memory deficits in the 8-arm water radial arm maze (WRAM), and
administration of riluzole attenuated these deficits. Our findings establish a potential therapeutic
intervention for memory deficits caused by glutamate dysregulation.
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Attenuation of Spatial Memory Impairment in a
Tau Mouse Model of Alzheimer’s Disease with Riluzole
Alzheimer’s disease (AD) affects one in every nine adults age 65 and older and is the
sixth leading cause of death in the United States (Alzheimer’s Association, 2014.) Worldwide,
the proportion of the population over 60 years of age is expected to double, with the total number
expected to reach approximately 2 billion by the year 2050 (World Health Organization, 2014).
Because aging is a strong predictor for developing AD (Plassman et al., 2007), the predicted rise
in the aging population, in addition to an increased life expectancy, is expected to be associated
with a dramatic increase in the incidence AD. If the current trend continues, healthcare, longterm care, and hospice care are projected to increase from a current mark of $214 billion to $1.2
trillion in 2050 (Alzheimer’s Association, 2014). Meanwhile, pharmacologic treatments for AD
have not been effective at slowing or halting the disease. It is imperative that alternative
therapeutic targets be explored.
AD is characterized by extracellular plaques composed of beta-amyloid (Aβ),
neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau, and neuron loss. The
discovery of mutations that increase the accumulation of Aβ, resulting in familial early onset
cases of AD (Tanzi et al., 1987), led to the development of the amyloid cascade hypothesis. This
hypothesis states that deposition and aggregation of Aβ is a critical step in the pathogenesis of
AD, ultimately leading to tau pathology and neurodegeneration (Hardy & Higgins, 1992). Most
research to date has focused on identification and development of anti-amyloid therapies (Bard et
al., 2000; Schenk et al., 1999; see Lannfelt et al., 2014 for review). Unfortunately, though
treatments targeting Aβ have been successful in reducing Aβ levels and plaques in AD patients,
this reduction has not coincided with an increase in cognitive functioning and does not prevent
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progressive neurodegeneration (Holmes et al., 2008). In addition, the severity of dementia
correlates with the number of NFTs in neocortical areas, rather than with the number of Aβ
plaques (Arriagada et al., 1992). Newer treatments including anti-Aβ antibodies prevent
downstream effects of toxic Aβ such as loss of dendritic spines and reverse behavioral deficits in
a mouse model of AD (Zago et al., 2012). Unfortunately, in clinical trials, Aβ antibody treatment
had no effect on individuals with mild-to-moderate AD (Doody et al., 2014). In addition,
evidence suggests that tau pathology, once initiated, becomes self-sustaining and Aβindependent (Katsuno et al., 2005). Targeting only Aβ, after the onset of tau pathology, is
unlikely to alleviate cognitive deficits, as evidenced by the inability of Aβ immunotherapy to
reduce tau phosphorylation or tau-mediated pathology (Oddo et al., 2004).
Similarly, tau dysfunction can lead to neurodegeneration even in the absence of Aβ
pathology (Hutton et al., 1998). Diseases in which tau hyperphosphorylation leads to cell
dysfunction and cell death are collectively known as tauopathies, with AD being the most
common of these diseases. In mouse models of tauopathies, all tau mice exhibiting tau pathology
eventually develop cognitive deficits (Arrendash et al., 2004), and neuronal loss is a hallmark of
tau mouse models (Spires et al., 2006). In contrast, though all mice expressing Aβ mutations
eventually develop amyloid plaques, some mice exhibit minimal or no cognitive deficits and
little to no neuronal loss (Gruart et al., 2008). Interestingly, knocking out endogenous mouse tau
in transgenic mice expressing human amyloid precursor protein (APP) protects against Aβmediated toxicity and reduces cognitive deficits, suggesting tau is necessary for Aβ-induced
toxicity (Roberson et al., 2007). The cleavage of APP results in the production of Aβ peptides
(see Nhan et al., 2015 for review). If the reduction of tau attenuates cognitive decline even in the
presence of Aβ, then identifying tau and the downstream effects mediated by tau could lead to
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new therapies that significantly improve the cognitive decline associated with AD. In addition,
tau may mediate neuronal death through hyperactivity of brain regions.
Hyperactivity of areas of the memory network of the brain, such as the hippocampus, has
been observed in patients at risk for the development of AD, including individuals with mild
cognitive impairment (MCI) (Dickerson et al., Hamalainen et al., 2007; Huijbers et al., 2015) and
young healthy adult apolipoprotein E4 (APOE-ε4) allele carriers (Dennis et al., 2010). Presence
of the APOE-ε4 allele is a significant genetic risk factor associated with the development of lateonset AD (Corder et al., 1993; (see Huang, 2011 for review). Initially it was believed that the
observed hyperactivity was a compensatory response where individuals with genetic risk for AD
required additional effort from multiple brain regions to achieve similar memory performance
compared to individuals not at genetic risk (Bondi et al., 2005). However, it is now believed that
this hyperactivity is detrimental and contributes to memory impairment associated with AD
pathology. For instance, individuals with AD have an increased risk for seizures compared with
individuals without AD of the same age (Amatniek et al., 2006). Also, seizure and epileptiform
activity is associated with earlier age of onset of cognitive impairments in individuals with MCI
and AD, with these symptoms often preceding diagnosis (Vossel et al., 2013).
Research using animal models provides further support for the impairing effects of
hyperactivity, and the relationship between hyperactivity and AD. Mouse models of AD
demonstrate hyperactivity prior to memory deficits (Bezzina et al., 2015). In addition, using a
regulatable mouse model of AD, abnormal EEG activity occurred following APP expression and
was delayed when APP expression was suppressed (Born et al., 2014). In addition, the observed
hyperactivity is related to behavioral performance. Aged rats demonstrating hyperactivity in the
hippocampus showed improved memory performance in spatial memory tasks following
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administration of treatment to decrease excess activity in the hippocampus (Koh et al., 2010).
Using a mouse model of AD, treatment to reduce the excess neuronal activity reduced
impairments in learning and memory and reversed deficits in synaptic transmission in the
hippocampus (Sanchez et al., 2012). Finally, in direct contrast to the hypothesis of compensatory
action in the memory network, a reduction in hippocampal activity in individuals with MCI did
not result in a worsening of memory performance as a consequence of reduced activity; rather,
the reduced activity resulted in improved performance in behavioral testing (Bakker et al., 2012).
These studies suggest that the observed hyperactivity may result in damage to the brain and may
also be permissive for the development of AD.
Although the exact role is not known, it is believed that tau mediates hyperactivity. First,
reducing the levels of endogenous tau protects against excitotoxin-induced seizures, where
induced seizure severity and onset were reduced in mice with reduced levels of tau (Roberson et
al., 2007). Because Aβ levels were not altered, it is believed that tau was responsible for
mediating this relationship. In addition, reduction of tau prevents spontaneous epileptiform
activity and reduces the severity of seizures in a mouse model of AD (Roberson et al., 2011). In
fact, there is a correlation between total tau protein levels found in the brain and the level of
seizure activity in non-transgenic mice (DeVos et al., 2013). Similarly, knockdown of tau
expression reduces seizure activity (Li et al., 2014). Overall, how exactly tau mediates
hyperactivity is not known. It has recently been suggested that tau may alter glutamate receptor
functioning (Warmus et al., 2014). Growing evidence, including our own data (Hunsberger et al.,
2014), indicates that glutamate dysregulation is critical to the pathophysiology of AD.
Addressing alterations in glutamatergic signaling may have therapeutic potential for those at risk
for developing AD.
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The glutamate life cycle
Glutamate is the most common excitatory neurotransmitter in the central nervous system
(CNS) (Daniels, Miller, & DiAntonio, 2011) and is synthesized presynaptically from glucose or
glutamine (Hamberger et al., 1979). Once synthesized, glutamate is packaged into synaptic
vesicles by vesicular glutamate transporters (VGLUTs) (Daniels et al., 2011). VGLUTs control
the amount of glutamate that is released into the synapse (Wojcik et al., 2004) when calcium
enters the presynaptic terminal, causing the glutamate-containing vesicle to fuse with the
terminal membranes (Sharma & Vijayaraghavan, 2003).
After being released into the synapse, glutamate can bind to either ionotropic or
metatropic glutamate receptors (mGluRs) (Hollmann, Hartley, & Heinemann, 1991). Because Nmethyl-D-aspartate receptors (NMDARs) are particularly important in the pathophysiology of
AD (Reisberg et al., 2003), NMDARs will be described in greater detail. NMDARs are located
synaptically (S-NMDAR) or extra-synaptically (E-NMDAR) (Hardingham, Fukunaga, &
Bading, 2002; Isaacson, 1999; Kullmann, Erdemli, & Asztély, 1996). S-NMDARs are activated
by glutamate in the synapse, whereas E-NMDAR activation requires glutamate spillover from
the synapse, which typically occurs when extracellular glutamate levels are high (Hardingham et
al., 2002). Termination of glutamate signaling occurs via reuptake by astrocytic, sodiumdependent glutamate transporters, including GLAST and GLT 1 (Pitt et al., 2003). After
glutamate is cleared from the synapse, it is converted within astrocytes to glutamine (Sonnewald,
Westergaard, & Schousboe, 1997; Lieth et al., 2001). Glutamine is released into the extracellular
space for uptake by presynaptic neurons, where it is converted back to glutamate, primarily by
glutaminase, thus continuing the glutamate-glutamine cycle (Sibson et al., 1997).
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Below, a brief overview of glutamate’s role as a neurotransmitter is described, followed
by evidence demonstrating glutamate’s role in the pathophysiology of AD.
Why target glutamate?
Glutamate, though essential for memory and learning (Jay, Zilkha, & Obrenovitch, 1999),
can cause cell death (Esclaire et al., 1997) by overstimulating E-NMDARs. This process, termed
excitotoxicity, can occur via two mechanisms: increased glutamate release into the synapse or
decreased glutamate clearance from the synapse. When glutamate levels are regulated, glutamate
is released into the synapse and activates primarily only S-NMDARs; however, if extracellular
glutamate accumulates, the extracellular glutamate spills over from the synaptic region and
activates E-NMDARs. Activation of S-NMDARs has neuroprotective effects, by promoting
brain derived neurotrophic factor (BDNF) expression, and increases learning and memory by
activating cAMP response element-binding protein (CREB) (Hardingham et al., 2002). In
addition, activation of S-NMDARs leads to the induction of long-term potentiation (LTP), which
is critical for learning and memory (Lu et al., 2001). In contrast, activation of E-NMDARs
deactivates CREB (Hardingham et al., 2002), activates long-term depression in regions of the
hippocampus (Lu et al., 2001), and induces neuronal death (Hardingham et al., 2002). In
addition, activation of E-NMDARs increases tau hyperphosphorylation by increasing the activity
of kinases that phosphorylate tau (Allyson et al., 2010).
Using a tau mouse model of AD, our lab recently found a significant increase in
hippocampal VGLUT expression, leading to increased glutamate release, and a decrease in
glutamate clearance (Hunsberger et al., 2014). Because these alterations in glutamate signaling
may be responsible for memory deficits, which are observed in the tau mouse model of AD
(Hoover et al., 2010; Hunsberger et al., 2014; Ramsden et al., 2005; SantaCruz et al., 2005), we
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hypothesized that administering treatment to regulate glutamate signaling would attenuate these
memory deficits.
To test this hypothesis, we used riluzole, an FDA-approved medication for the
neurodegenerative disease amyotrophic lateral sclerosis (ALS). Riluzole decreases glutamate
release by reducing activation of voltage-dependent sodium channels, and increases glutamate
clearance by increasing glutamate transporter expression (Liepert et al., 1997). We treated
rTg(TauP301L)4510 mice (herein referred to as TauP301L) with riluzole and examined memory
performance. TauP301L mice exhibit memory deficits, tau pathology, and neuron loss (Ramsden
et al., 2005). We predicted riluzole would attenuate the progression of memory decline typically
observed in TauP301L mice following the expression of mutant tau (Ramsden et al., 2005). To
determine whether riluzole attenuated memory deficits in TauP301L mice, we employed the
eight-arm water radial arm maze task (WRAM), a task that examines spatial working memory
(Engler-Chiurazzi et al., 2011).
Water radial arm maze (WRAM)
The WRAM is a hippocampal-based task that can be used to assess both reference
memory errors and working memory errors in rodents (Gresack et al., 2003; Hyde et al., 1998,
Lockrow et al., 2011). Reference memory errors are a measure of long-term memory, whereas
working memory errors are a measure of short-term memory (Ciobica et al., 2012; Mladin et al.,
2014; Stéphan; 2001) Reference memory errors reflect errors in learning of information that
stays consistent throughout the entire experiment, such as the location of spatial cues around the
room. This type of memory is required in order to learn the rules of the task (Shukitt-Hale et al.,
2004). On the other hand, working memory errors reflect deficits in the ability of the rodents to
hold changing information in memory (Frick et al., 1995). Working memory involves retaining
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information for short periods of time in regards to trial-specific details. For example, in the
WRAM, after a platform is located, it is removed from the maze for all subsequent trials of that
specific testing day. Because a trial-specific change occurred (i.e. the removal of a found
platform), retaining the new information (i.e. there is no longer a platform in the just-chosen
arm) would constitute working memory. Both reference and working memory errors can be
examined using the WRAM procedure, a benefit of this task over those that primarily measure
reference memory errors, such as the Morris water maze.
The ability to measure both types of errors is important in part because differential effects
on working and reference memory can be observed. For instance, whereas estrogen treatment
improves working memory performance, it does not affect performance on reference memory
tasks in female rats (Fader et al., 1999). In addition, specific memory impairments appear to
precede different disease states. For example, spatial reference memory errors are observed prior
to motor impairments in experimental autoimmune encephalomyelitis, a mouse model of
multiple sclerosis (Dutra et al., 2013). Further, reference and working memory are separately
affected in different animal models of disease. Mice lacking specific subunits of NMDA
receptors in the hippocampus exhibit impaired working memory, but normal reference memory
(Bannerman et al., 2008; Niewoehner et al., 2007). This coincides with findings of impaired
working memory functioning in mouse and rat models of AD (Cotel et al., 2012; Mustroph et al.,
2012). However, knocking out the APOE gene, using APOE KO mice, improves reference
memory compared to controls, without affecting working memory (Avdesh et al., 2011).
Because both spatial reference and working memory are negatively affected in rodent models as
well as in individuals with AD (Crawford et al., 2013; Stopford et al., 2012), assessing both of
these types of memory errors in our mouse model of AD has clinical implications.
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Statement of the problem
Alzheimer’s disease is a progressive neurodegenerative disorder that currently has no
cure and is the most common form of dementia (Alzheimer’s Association, 2013). AD is
characterized by intracellular neurofibrillary tangles (NFTs) containing hyperphosphorylated tau
and extracellular plaques comprised of beta-amyloid (Aβ). Pharmacologic interventions have
been effective in reducing Aβ levels; however, these reductions have not led to an increase in
memory functioning (Holmes et al., 2008). Because of the shortcomings of research focusing on
Aβ, it is necessary to investigate other possible causes and therapeutic targets, such as tau and
downstream alterations produced following tau pathology.
While the exact mechanism by which hyperphosphorylated tau causes cell death is not
known, prior research (Amadoro et al., 2005; Esclaire et al., 1997; Hoover et al., 2010; Tackenberg
et al., 2013) shows a relationship between hyperphosphorylated tau and increased activation of ENMDARs by glutamate. Because glutamate increases tau phosphorylation (Jämsä et al, 2006),
reductions in extracellular glutamate may halt the accumulation of hyperphosphorylated tau
deposits.
Riluzole, an FDA-approved treatment for amyotrophic lateral sclerosis, reduces the
spontaneous release of glutamate (Chéramy et al., 1992) and increases glutamate uptake (Liepert
et al., 1997), leading to decreases in extracellular glutamate (Fumagalli et al., 2007). The ability
of riluzole to increase glutamate uptake is mediated by glutamate transporters located on
astrocytes, such as GLT-1 (Banasr et al., 2010; Fumagalli et al., 2008). Additionally, the
pharmacokinetic profile of riluzole is ideal: 90% is absorbed following oral administration, the
half-life is 12 hours, and primarily only mild side effects have been observed (Food and Drug
Administration, 2008). The most common side effects are nausea and asthenia, which includes
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muscle weakness and fatigue (Miller et al., 2012; Lemmon et al., 2015). To determine whether
decreasing extracellular glutamate attenuates AD-related memory deficits, we administered
riluzole to TauP301L mice and measured spatial memory performance with the WRAM.
Method
Subjects
In total, 68 male and female mice were used (Figure 1A). Original transgenic mice were
donated by Dr. Karen Ashe (University of Minnesota). Transgenic mice were generated using a
system of responder and activator transgenes, which has been described previously (Ramsden et
al., 2005; SantaCruz et al., 2005). The activator transgene in a mouse line of a 129S6 background
strain consists of the tet-off tetracycline transactivator (tTA) open reading frame placed
downstream of calcium/calmodulin kinase II (CaMKII) promoter elements. Responder mice in
an FVB background strain were generated by placing a tetracycline- responsive element (TRE)
upstream of cDNA encoding human four-repeat tau lacking the N-terminal sequence (4R0N)
with the P301L mutation. Heterozygous responder and activator mice were bred together to
produce TauP301L mice (TauP301L/tTA: +,+) and three controls (+,-), (-,+), and (-,-). Only the
(-,+) control was used because littermate controls do not express tau or exhibit behavioral
impairments (Ramsden et al., 2005; SantaCruz et al., 2005), but the use of (-,+) mice allow us the
ability to control for the expression of tTA (Hunsberger et al., 2014).
Through the use of CaMKII promoter, expression of tau is restricted to the hippocampus
and neocortex, regions altered in AD (Pearson et al., 1985) (Figure 1B). The use of the tet-off
system allows for the regulatable expression of tau. In the tet-off system, the tTA protein binds to
TRE, which allows transcription and protein expression to occur (Liu et al., 2008). If
doxycycline, a tetracycline derivative, is introduced to the drinking water or food, the tTA
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protein cannot bind to TRE leading to the suppression of tau expression. Because the expression
of P301L tau during development can produce alterations not observed if P301L tau is first
expressed in adulthood (Caouette et al., 2013), P301L tau expression was suppressed using
doxycycline during brain development to ensure deficits and morphological changes in the brain
not related to AD did not occur. Mice received 40 parts per million (ppm) doxycycline hyclate
via water bottles from birth until 2.5 months of age. Doxycycline was purchased from SigmaAldrich (St. Louis, MO, USA). Breeder dams were placed on doxycycline two weeks prior to
breeding to ensure maternal levels stabilized before pregnancy. Mice were group housed 3 – 5
per cage in a temperature and humidity-controlled colony room with a 12:12 light/dark cycle.
Food was provided ad libitum. All experimental procedures were approved by the West Virginia
University Animal Care and Use Committee.
Experimental design & riluzole administration
To ensure differences between TauP301L mice and control littermates were not present
prior to the onset of tau expression, behavioral testing was conducted with the water radial arm
maze (WRAM) at 2.5 months of age while the mice were still on doxycycline. Once it was
confirmed that deficits were not present prior to the expression of tau, TauP301L mice were
removed from doxycycline and pseudo-randomly assigned to vehicle or riluzole treatment
groups based on pre-tau WRAM performance, resulting in 3 groups: Veh-Controls (N = 23; n =
11 females, n =12 males), Veh-TauP301L (N = 24; n = 9 females, n = 15 males), and RilTauP301L (N = 21; n = 13 females, n = 8 males). Ril-TauP301L mice received riluzole, whereas
Veh-Controls and Veh-TauP301L mice received vehicle alone.
Riluzole was purchased from Selleck Chemicals (Houston, TX, USA). Riluzole and 1%
w/v saccharin (vehicle) was mixed together in deionized water for approximately 2 hours under
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low heat until completely dissolved. The dissolved riluzole was then administered to mice via
water bottles changed every three days. Water bottles were weighed daily, and the concentration
of riluzole was adjusted every 72 hours such that intake remained at approximately 12.5
mg/kg/day per mouse for each cage. This dose was chosen because it has been shown to increase
GLT-1 expression, restore brain-derived neurotrophic factor expression, and does not affect
locomotor activity when administered to mice via drinking water (Gourley et al., 2012). In
human patients, two of the most frequent side effects of riluzole include nausea and asthenia, or
general weakness (Miller et al., 2012). Throughout testing, body weights of the mice were
recorded and swim speed was measured during behavioral testing. No differences in bodyweight
were observed among the treatment groups at 2.5, 5, or 7.5 months of age (ps > .10). In addition,
swim speeds did not differ in the Morris water maze (ps > .10). These results suggest that the
dose of riluzole administered in the study was not toxic and did not produce nausea or asthenia.
Mice underwent further memory testing at 5 and 7.5 months of age, after 2.5 and 5
months of tau expression, respectively. At both time points, mice underwent WRAM testing,
followed by additional cognitive testing. At the final time point, the last test completed was the
visible platform task. Although other tests were used, the current project will focus solely on the
results obtained from WRAM and visible platform testing. During testing at 7.5 months of age, a
male mouse from the Veh-Controls group died, reducing the sample size for testing at 7.5
months of age.
Water Radial Arm Maze. The WRAM was performed as previously described
(Bimonte-Nelson et al., 2003). The maze was constructed of white plastic with 8 arms (10.4 cm
wide x 38.1 cm long x 38.9 cm in high) spaced 5 cm apart. The middle circle, from which the
eight arms extend, has a diameter of 38.9 cm. The maze was filled with room temperature water
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(approximately 21°C) and made opaque with white non-toxic paint. The distance from the water
level to the top of the maze was approximately 5 cm. Four of the arms contained platforms
located 1 cm below the surface of the water. The location of the platforms were counterbalanced
across the groups, but remained fixed for a particular mouse for the duration of testing at a
particular age. A platform was never in more than two adjacent arms or in the “start arm” from
which a mouse was released. Salient extra-maze cues remained constant for the duration of
testing at a particular age. However, both the location of the platform arms and the cues changed
for testing at subsequent ages.
Once released from the start arm, the mouse had 2 minutes to locate a hidden platform. If
the allotted time expired, the mouse was guided to the nearest platform. Once a platform was
found, the mouse remained on the platform for 15 seconds. At that point, the mouse was
removed and placed in the holding cage lined with paper towels and warmed to ~31 °C by a
heating pad and heat lamp for 30 seconds to prevent hypothermia. During the interval, the justchosen platform was removed. After 30 seconds elapsed, the mouse was placed in the start arm
again and allowed to locate a different platform. Each mouse was given 4 trials per session and
one session per day. One platform was removed after each trial until only one platform remained
in trial 4. Thus, each subsequent trial resulted in an increase in memory load, as the mice had to
remember not only the locations of the remaining platforms, but also the location of the
platforms that had already been found and removed (Bimonte-Nelson, et al., 2003).
Each mouse was given 1 session per day for 11 consecutive days. Day 1 was considered a
training session because the mice did not have previous experience in the maze, whereas days 211 were considered the testing sessions for acquisition (Engler-Chiurazzi et al., 2011). On day
12, a four-hour delay was inserted between trials 2 and 3. At 5 and 7.5 months of age, a 13th day
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of testing was added, and a six-hour delay was inserted between trials 2 trial 3. Delays were
inserted to increase memory demand for the trials following the delay, i.e., trials 3 and 4 (EnglerChiurazzi et al., 2011).
An arm entry was defined as all four paws entering into an arm of the maze. Working
memory correct errors were defined as the number of first and repeat entries into any arm where
a platform had been during a previous trial. Reference memory errors were defined as the
number of first entries into any arm that never contained a platform. Working memory incorrect
errors were defined as the number of repeat entries into an arm that never contained a platform,
i.e., repeat entries into a reference memory arm (Figure 2). Errors were analyzed for each daily
session of acquisition (days 2-11). For days 12 and 13, trials 1-4 were analyzed (Braden et al.,
2010).
Visible Platform Test. To ensure any deficits observed in the WRAM were not due to
visual or motor deficits, the visible platform test was performed as previously described
(Bimonte-Nelson et al., 2003) at the end of the experiment at 7.5 months of age. The tub (61 cm
length x 61 cm width x 21 cm height) was partially filled with room temperature water
(approximately 21°C) made opaque with white non-toxic paint. The distance of the water from
the top of the tub was approximately 6.4 cm. A black platform, with a flag raised 13 cm in height
containing an “S” shaped character mounted on top, was placed approximately 2.5 cm above the
water level. Extra-maze cues were removed from the testing area, and white curtains were hung
around the testing room. Briefly, a mouse was placed into the tub so that it entered facing the
wall opposite the platform. The mouse was given 2 minutes to swim to the platform. If the
mouse found the platform within the allotted time limit, the mouse remained on the platform for
20 seconds; if the mouse did not find the platform within the allotted time limit, the mouse was
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gently guided to the platform. After each mouse completed the first trial, the platform was
moved to a previously determined location near the back wall of the tub. All mice were given 5
independent trials, with approximately 10 minutes in between each trial.
Statistical Analyses
All statistical analyses were performed using JMP (SAS, Cary, NC, USA). ANOVAs
were used to examine differences in memory performance for each error at each age. For all
analyses, main effects of Group (Veh-Controls, Veh-TauP301L, and Ril-TauP301L), Sex (Male
vs Female), and the Group*Sex interactions were assessed. Due to the longitudinal nature of this
study, repeated measures ANOVAs (RMANOVA) were also used to assess changes in cognitive
performance with longer durations of tau expression. Day or Trial served as the within-subject
variables for RMANOVA analyses. All significant omnibus tests were followed by Dunnett's
post-hoc analyses with Veh-TauP301L used as the comparison group. The critical alpha level
was set to 0.05, and values in the figures represent means ± SEM.
Results
Behavioral Testing
2.5 Months of age: Pre-tau. During acquisition trials at 2.5 months of age, significant effects of
Day for time [F(9,522) = 3.39, p = .0005], WMC [F(9,522) = 3.33, p = .0006], WMI [F(9,522) =
5.22, p < .0001], and REF [F(9,522) = 8.74, p < .0001] were observed. For time, WMI, and REF,
mice improved with additional training, whereas for WMC, mice made more errors with
additional training (Figure 3), suggesting that mice may require additional training in order to
reduce WMC errors as opposed to REF or WMI errors. Though male mice, regardless of Group
status, took longer to find the platform initially, males and females performed similarly with
additional training [Day*Sex: F(9,522) = 2.00, p = .04] (Figure 4). There were no differences,
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however, among the Groups (Veh-Controls, Veh-TauP301L, and Ril-TauP301L) for any
measure (ps > .10) (Table 2), suggesting similar acquisition prior to the onset of tau expression.
On Day 12, a 4-hour delay was inserted between trials 2 and 3 to increase the memory
load (Braden et al., 2010), and the number of errors was compared. Male mice, regardless of
Group status, made significantly more WMI errors than female mice [Sex: F(1,58) = 3.96, p
= .05] (Figure 5). No other differences were observed prior to the expression of tau (ps > .10)
(Table 3), indicating similar overall pre-tau memory performance among the Groups.
5 and 7.5 Months of age: Post-tau Acquisition. Unless otherwise noted, there were significant
Day effects for time, WMC, WMI and REF errors at 5 and 7.5 months of age (ps < .05) and will
not be discussed in detail (Figure 6, 8).
Because no differences were found at 2.5 months of age, prior to tau expression, mice
were tested at 5 months of age, 2.5 months post tau expression. During acquisition trials at 5
months of age, there was no effect of Day for WMC, showing that no improvement was
observed in WMC with increased training [F(9,522) = 1.05, p < .40] (Table 4). A significant
interaction in REF errors was observed [Day*Group: F(18,522) = 1.77, p < .05], where VehControls [F(9,198) = 3.98, p < .0001] and Ril-TauP301L [F(9,180 = 4.76, p < .0001] improved
in REF performance with additional training, whereas Veh-TauP301L mice did not [F(9,207] =
1.59, p = .12] (Figure 6D). In addition, male mice took longer to complete the trials than female
mice [Sex: F(1,58) = 6.03, p = .02], and male mice made more WMC [Sex: F(1,58) = 4.21, p =
0.04], WMI [Sex: F(1,58) = 5.10, p = .03], and REF errors than female mice [Sex: F(1,58) =
5.90, p = .02] (Figure 7).
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Finally, at 7.5 months of age, after 5 months of tau expression, there were no significant
effects of Group or Sex, and there were no Sex*Group interactions for any measure (ps > .10)
(Table 5).
5 and 7.5 Months of age: Delays. Following analysis of acquisition, or testing days in which
mice learned the task, we analyzed testing days in which a day was inserted. A RMANOVA at 5
months of age of trials 1, 2, 3, and 4 of Day 12 was conducted to determine the effects of an
increasing memory load when a 4-hour delay was inserted between trials 3 and 4 (EnglerChiurazzi et al., 2011). There were no Group, Sex, or Group*Sex interactions (ps > .10) (Table
6), suggesting a 4-hour delay was not sufficient to reveal memory deficits after 2.5 months of tau
expression.
To determine if a longer delay would unmask memory deficits, a 6-hour delay was
inserted between trials 3 and 4 on Day 13 to further increase difficulty (Engler-Chiurazzi et al.,
2011). A RMANOVA of trials 1, 2, 3, and 4 of Day 13 revealed Veh-TauP301L mice made
significantly more WMI errors [Group: F(2,58) = 5.49, p = 0.007], an effect attenuated by
riluzole (Figure 9). Veh-TauP301L mice repeatedly returned into arms which never contained a
platform, demonstrating deficits in a measure of short-term memory. No other differences for
any error were observed (Table 7).
We next analyzed delay trials at 7.5 months of age because this allowed for the longest
amount of tau expression. When a 4-hour delay was inserted on Day 12 at 7.5 months of age,
after 5 months of tau expression, a RMANOVA of trials 1-4 of Day 12 revealed that VehTauP301L mice made significantly more REF errors as compared to Veh-Controls [Group:
F(2,57) = 4.72, p = .01] (Figure 10). No other differences for any error were observed (Table 8).
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Analysis of trials 1-4 of Day 13 at 7.5 months of age demonstrated that Veh-TauP301L
mice made more WMI errors with increasing memory load [Trial*Group: F(6,171) = 2.68, p
= .02] (Figure 11). This shows that on the trial with the highest memory load, Veh-TauP301L
mice repeatedly entered arms which never contained a platform, demonstrating deficits in shortterm memory. This effect was reduced by administration of riluzole. No effects of Group, Sex, or
Group*Sex interactions were observed for any other error (Table 9).
Finally, memory performance at 5 and 7.5 months of age was compared among the
groups (Table 10). At each age, data from Trials 3 and 4 were averaged together and then
analyzed because these trials follow the 6-hour delay and have the highest memory demand
(Engler-Chiurazzi et al., 2011). A RMANOVA of trials 3 and 4 following the 6-hour delay on
Day 13 at 5 and 7.5 months of age revealed Veh-TauP301L mice took more time to complete
trials 3 and 4 [Group: F(2,57) = 4.02, p = .02] (Figure 12) and made more WMI errors [Group:
F(2,57) = 7.96, p = .0009] (Figure 13), regardless of age. WMI errors committed at both ages
were rescued by the administration of riluzole.
Visible platform
To determine whether any mice were demonstrating visual or motor deficits, visible
platform training was conducted at the conclusion of behavioral testing. There were no
differences in time to find the visible platform [Group: F(2,57) = 2.10, p = .13; Sex: F(1,57) =
0.80, p = .37; Group*Sex: F(2,57) = 2.63, p = .08] (Table 11). Results suggest there were no
differences in visual or motor deficits in the mice in the current study.
Discussion
We examined the effectiveness of riluzole in attenuating memory deficits using a
TauP301L mouse model of AD. Altered glutamate signaling has been observed in TauP301L mice
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and correlates with memory performance in hippocampal-dependent tasks (Hunsberger et al.,
2014). To determine if attenuating glutamate dysregulation could rescue the observed cognitive
impairments, we administered riluzole, which regulates glutamate signaling (Liepert et al., 1997),
and examined the effects on memory using the hippocampal-dependent water radial arm maze
(WRAM). Our findings suggest that TauP301L mice exhibited memory deficits, an effect
attenuated by riluzole.
The WRAM is a spatial water maze memory task that requires animals to use spatial cues
around the room to learn the position of hidden platforms. The use of the WRAM eliminates
potential confounds due to motivation to locate food and also avoids the potential issue of
thigmotaxic behavior, which occurs when mice swim close to the walls in circular tubs and do not
learn a search strategy (Bimonte-Nelson et al., 2003). The WRAM also has the benefit of
increasing memory load due to the removal of a platform following each trial (Bimonte-Nelson et
al., 2003) and the insertion of delays following acquisition testing (Braden et al., 2010).
Results from the WRAM indicated that, as anticipated, there were no differences between
TauP301L and Control mice prior to the onset of tau expression. However, there were differences
between males and females on the delay trial. Similarly, males perform better than females in
WRAM testing (Gresack & Frick, 2003). However, in the current study, male mice made more
errors than female mice. The reported difference in this study may be due to the use of different
background strains. In addition, different testing procedures were used. In the current study,
acquisition consisted of 11 days, followed by testing days in which a delay was inserted; during
pre-tau testing, male and female mice displayed similar performance during acquisition; however,
male mice made more errors on the delay trial, which was not conducted in the study by Gresack
and Frick (2003).
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At 5 months of age, 2.5 months post-tau expression, results from the WRAM indicated that
Veh-TauP301L mice made significantly more errors than Ril-TauP301L mice. However, there was
no significant difference in errors made between Veh-TauP301L mice and Veh-Controls. It is
possible that this time point may represent an early stage in the progression from normal memory
functioning to impaired memory functioning. At 7.5 months of age, 5 months post-tau expression,
Veh-TauP301L mice made significantly more errors than Ril-TauP301L mice and Veh-Controls.
Riluzole not only attenuated memory deficits but resulted in TauP301L memory performance that
was similar to the performance of controls. The findings of this study suggest that TauP301L mice
that received riluzole displayed similar memory performance as non-transgenic mice. This
suggests that regulating glutamate levels attenuates memory deficits in TauP301L mice.
WRAM testing allows for measurements of time to find the platform, working memory
correct errors (WMC), working memory incorrect errors (WMI), and reference errors (REF).
Although time to find the hidden platform can be used for analysis, potential confounds when
analyzing time to find the platform include swim speed and irregular swim behavior such as
floating. Because tracking software was not used for WRAM testing, swim speed could not be
analyzed. WMC errors did not differ among the groups. One potential reason for this could be the
age at which testing was conducted. We conducted memory testing at 2.5, 5, and 7.5 months of
age, while suppressing tau expression for the first 2.5 months. Because severe memory
impairments are not yet expected after 2.5 and 5 months of tau expression, it is possible that WMC
errors are not sensitive enough to detect such subtle memory impairments. Rather WMC errors
may be a more sensitive measure for older mice, after a longer period of tau expression. WMI
errors were the most sensitive error in the current study. WMI errors, which are the number of
times a mouse re-enters an arm that never contained a platform, have qualities similar to
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preservative behavior. Preservative behavior is defined as a continuation of behavior without an
appropriate stimulus (Son et al., 2013) and is often seen in patients with AD and other dementias
(Lamar et al., 1997; Possin et al., 2012). In the current study, we observed an increase in WMI
errors as trials progressed and became more difficult.
Throughout each day of WRAM testing, memory load increases (Bimonte-Nelson et al.,
2003), meaning that, on each successive trial, mice have to remember more information. Following
the first trial, in order to complete the task, the mice must remember where the four platforms are
located and which platforms have already been located. The addition of a delay further increases
the memory load of trials three and four. Increasing memory load is relevant to Alzheimer's disease
patients because the hippocampus, which is damaged in AD (Kril et al., 2002; Salat et al., 2010),
is necessary for normal performance in memory tasks with high memory load (Sannino et al.,
2012). In addition, increasing the memory load by increasing the delay time may also have
relevance to disorders with hippocampal dysfunction. Finally, because the current study examined
memory deficits at an early time point in the progression of disease pathology, increasing the
memory load by increasing the time of the delays may be necessary to ensure the task is sensitive
enough to identify differences in memory performance among groups.
Individuals with AD display working memory impairments, which become more
pronounced as increased information is presented, characteristic of a high memory load (Stopford
et al., 2012). Also, individuals with AD display impairments in memorizing and retracing a
sequence of body turns when tested in a navigation task developed for mice and adapted to humans
(Bellassen et al., 2012; Bianchini et al., 2014). Specifically, short-term memory in relation to
navigating in an unfamiliar environment is impaired in the early stages of AD, where patients with
AD are unable to identify similar landscape images when topographical features are changed. (Bird
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et al., 2010). WRAM testing also measures reference memory errors. Reference memory involves
being presented with information that stays constant over time, whereas working memory involves
using information that changes with a short duration of time (Gamoh et al., 1999; Jarred et al.,
1984). Spatial reference memory and spatial working memory appear to have different underlying
processes. For instance, mice lacking a specific glutamate receptor subunit (GluR1) display
working memory deficits but not reference memory impairments (Reisel et al., 2002; Schmitt et
al., 2003). Further research on how these two types of memory work together, yet also function
separately, is warranted.
Spatial memory was rescued in the present study by the administration of riluzole. While
it is believed this rescue occurred through regulating glutamate levels, the exact mechanisms by
which riluzole alters glutamate regulation is not fully understood. Riluzole increases the rate of
glutamate uptake (Azbil, 2000), which is mediated by astrocytic glutamate transporters such as
GLT-1 (Banasr et al., 2010, Fumagalli et al., 2008). Riluzole also decreases the amount of
glutamate that is released. However, it is unclear if riluzole inhibits release by inhibiting voltagedependent calcium channels (Wang et al., 2004), sodium channels (Urbani & Belluzzi., 2000; Zona
et al., 1998), or potassium channels (Xu et al., 2001; Zona et al., 1998).
Riluzole shows translational potential because it increases astrocytic glutamate uptake even
at low concentrations (Santos Frizzo et al., 2004). Riluzole has shown anxiolytic-like effects
(Sugiyama et al., 2012), anti-depressant like effects (Gourley et al., 2012), and has shown
numerous neuroprotective effects including reducing neuron death and degeneration (Cabaj &
Slawinska et al., 2012; Carbone et al., 2012; Mazzone & Nistri., 2011;Verhave et al., 2012)..
Although the present study did not examine the direct ability of riluzole to regulate glutamate
levels, our lab examined the ability of riluzole to regulate glutamate using microelectrode arrays
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following the completion of behavioral testing. TauP301L mice demonstrated increased glutamate
release and decreased glutamate uptake, both of which were returned to control levels following
riluzole treatment.
A limitation of the present study is the absence of a control littermate group that received
administration of riluzole. Therefore, the effect of riluzole on mice without the P301L mutation
cannot be concluded from this study. The present study extends findings of the ability of riluzole
to improve memory performance in animal models of brain dysfunction, such as ischemia
(Malgouris et al., 1989). However, the present study did not determine whether riluzole
administration has the potential to improve memory performance in non-transgenic mice.
Although our lab has demonstrated the alteration of glutamate signaling in a commonly
used mouse model of AD, glutamate may not be the only cause of hyperexcitability leading to
neurodegeneration. For example, γ-aminobutyric acid (GABA) is the major inhibitory
neurotransmitter in the CNS (see Li & Xu, 2008 for review). Reductions in GABA signaling can
also result in hippocampal hyperexcitability (Lang et al., 2014; Nieto-Gonzalez et al., 2011;
Olmos-Serrano et al., 2010), presumably by reducing tonic inhibition of glutamatergic neurons. It
is plausible then that hyperactivity could be due to the interaction between reduced GABA activity
and increased glutamate activity. In addition, tau pathology has detrimental effects on GABAergic
neuron functioning, leading to altered synaptic plasticity and memory deficits (Levenga et al.,
2013). Determining the roles of the GABAergic and glutamatergic systems and how they interact
with tau to mediate hyperexcitability in neurodegenerative disorders should be further
investigated.
In conclusion, we administered riluzole to TauP301L mice to determine if regulating
glutamate levels could rescue memory deficits. Our results demonstrate that TauP301L mice
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exhibit memory impairments, and these deficits are attenuated with riluzole administration. Based
on our lab's findings of increased glutamate release and decreased glutamate clearance in
TauP301L mice (Hunsberger et al., 2014), combined with riluzole's ability to improve glutamate
signaling, glutamate regulation may be responsible for the attenuation of memory deficits that were
observed in this study. In addition, decreased glutamate clearance is observed in patients with AD
(Ferrarese et al., 2000; Masliah et al., 1996. Therefore, altering glutamate dysregulation has
clinical implications for AD patients. The findings from this study provide a first step towards the
development of an open-label investigation of riluzole for those at risk for AD.
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Figure 1. Design of study. (A) There were a total of 68 mice in the experiment, with a range of
21 to 24 mice in each group. (B) Tau P301L responder lines encode for human 4-repeat tau
lacking the amino-terminal sequence (4R0N). The activator line uses the CaMKIIα promoter to
restrict expression to the forebrain. The tTA binds to the tetO promoter to initiate transcription,
leading to production of the tau protein. (C) Tau expression was suppressed using doxycycline
hyclate (40 ppm) until 2.5 months of age. Mice were tested at 2.5, 5, and 7.5 months of age.

ATTENUATION OF TAU-MEDIATED MEMORY DEFICITS

39

Figure 2. Visual representation of errors on WRAM test. Following being released from the start
point on trial 2, entrance into an arm which previously contained a platform (represented by the
red circle) results in a working memory correct error (WMC). Entrance into an arm which never
contained a platform is considered a reference memory error (REF). Re-entry into an arm which
never contained a platform results in a working memory incorrect error (WMI). Thus, a WMI is
a repeated REF error.
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Figure 3. Similar performance among Groups prior to tau expression. There were no differences
among the Groups for time (A), WMC (B), WMI (C), or REF errors (D) during acquisition at 2.5
months of age, prior to the expression of tau (ps > .10). There were Day effects for time (p
= .0005), WMC (p = .0006), WMI (p < .0001), and REF errors (p < .0001).
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Figure 4. Sex differences in time to locate the platform prior to tau expression. There was a
significant Day*Sex interaction for time during acquisition at 2.5 months of age (p = .04). (**
p<.01)
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Figure 5. Male mice make more errors prior to tau expression. With the insertion of a 4-hour
delay, male mice made significantly more WMI errors than female mice on day 12 at 2.5 months
of age (p = .05).
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Figure 6. Veh-TauP301L mice exhibit deficits during acquisition at 5 months of age, 2.5 months
post-tau expression. There were significant effects of Day for time, WMI, and REF (ps < .0001).
A significant Day*Group interaction for REF errors was observed (p < .05) where Veh-Controls
and Ril-TauP301L improved in REF performance with additional training (ps < .0001) while
Veh-TauP301L mice did not (p = .12) (D). ( * p<.05 Veh-Controls vs. Veh-TauP301L, @ p<.01
Veh-TauP301L vs. Veh-Controls).
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Figure 7. Sex differences during acquisition at 5 months of age. During acquisition, male mice
took more time (p =.02) to locate the platforms (A), and made more WMC (p = .04) (B), WMI (p
= .03) (C) and REF errors (p = .02) (D) at 5 months of age, 2.5 months post-tau expression.
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Figure 8. Similar performance during acquisition at 7.5 months of age. There were significant
Day effects for time (A), WMC (B), WMI (C), and REF errors (D) (ps < .0001), where
performance improved with additional training at 7.5 months of age, 5 months post-tau
expression.
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Figure 9. Riluzole attenuates memory deficits in TauP301L mice at 5 months of age. During Day
13 with the 6-hour delay at 5 months of age, 2.5 months post tau expression, Veh-TauP301L
made significantly more WMI errors (p = .0007). (# # p<.01 Ril-TauP301L vs. Veh-TauP301L).
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Figure 10. Veh-TauP301L show impairments at 7.5 months of age. During Day 12 with a 4-hour
delay at 7.5 months of age, 5 months post-tau expression, Veh-TauP301L mice made more REF
as compared to Veh-Controls (p = .01). (** p<.01 Veh-Controls vs. Veh-TauP301L).
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Figure 11. Veh-TauP301L mice show impaired memory performance at 7.5 months of age. On
day 13, with the insertion of a 6-hour delay, Veh-TauP301L made significantly more WMI errors
overall with increasing memory load. Ril-TauP301L mice made less errors than Veh-TauP301L
mice; however, at the highest memory load, this difference was not significant. (* p<.05 VehControls vs. Veh-TauP301L).
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Figure 12. Veh-TauP301L mice take longer to locate the platforms at 5 and 7.5 months of age.
A RMANOVA of trials following the 6-hour delay at 5 and 7.5 months of age showed that VehTauP301L took longer to find the platform in trials following the delay (p = .02). (# p<.05 RilTauP301L vs Veh-TauP301L).
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Figure 13. Riluzole rescues memory performance at 5 and 7.5 months of age. RMANOVA of
trials following the 6-hour delay at 5 and 7.5 months showed that Veh-TauP301L made more
WMI errors in trials following the delay, an effect rescued by the administration of riluzole (p
= .0009). (* p<.05 Veh-Controls vs. Veh-TauP301L, # p<.05 Ril-TauP301L vs. Veh-TauP301L,
# # p<.01 Ril-TauP301L vs. Veh-TauP301L).
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Abbreviations
APOE-E4
APP
VGLUT
NMDAR

Apolipoprotein E type 4
Amyloid precursor protein
Vesicular glutamate transporter
N-methyl-D-aspartate receptor

S-NMDAR
E-NMDAR
WRAM
WMC
REF
WMI

Synaptic NMDAR
Extra-synaptic NMDAR
Water radial arm maze
Working memory correct error
Reference memory error
Working memory incorrect error

Table 1. Abbreviations of terms used throughout the document.
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2.5 M Acquisition
Time
WMC
WMI
F (2,58) = 1.27,
F (2,58) = 0.46,
F (2,58) = 0.15,
p = .29
p = .64
p = .86
Group
F (1,58) = 0.15,
F (1,58) = 0.12,
F (1,58) = 1.12,
p = .70
p = .73
p = .30
Sex
F (2,58) = 1.07,
F (2,58) = 0.91,
F (2,58) = 0.95,
p = .35
p = .41
p = .39
Group*Sex
F (9,522) = 3.39, F (9,522) = 3.33,
F (9,522) = 5.22,
Day
p = .0005***
p = .0006***
p < .0001***
F (18,522) = 1.17, F (18,522) = 0.89, F (18,522) = 1.01,
p = .28
p = .60
p = .45
Day*Group
F (9,522) = 1.01,
F (9,522) = 2.00, F (9,522) = 1.14,
p = .33
p = .43
Day*Sex
p = .04*
Day*Group F (18,522) = 1.23, F (18,522) = 0.71, F (18,522) = 1.32,
p = .24
p = .80
p = .17
*Sex
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REF
F (2,58) = 0.19,
p = .83
F (1,58) = 0.16,
p = .69
F (2,58) = 0.31,
p = .74
F (9,522) = 8.74,
p < .0001***
F (18,522) = 0.81,
p = .69
F (9,522) = 1.45,
p = .16
F (18,522) = 1.21,
p = .25

Table 2. Acquisition. At 2.5 months of age, pre-tau expression, there were no Group differences
in errors made for any error. There were significant Day effects for all errors (ps > .001) and
there was a significant Day*Sex interaction for time to find the platform during acquisition trials
(p < .05).
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Group
Sex
Group*Sex
Trial
Trial*Group
Trial*Sex
Trial*Group
*Sex

Time
F(2,58) = 0.50,
p = .61
F(1,58) = 0.20,
p = .66
F(2,58) = 0.76,
p = .47
F(3,174) = 50.39,
p < .0001***
F(6,174) = 0.29,
p = .34
F(3,174) = 0.67,
p = .57
F(6,174) = 0.63,
p = .70

2.5 M day 12 trials 1-4
WMC
WMI
F(2,58) = 0.06,
F(2,58) = 0.26,
p = .94
p = .77
F(1,58) = 0.00,
F(1,58) = 3.96,
p = .94
p = .05*
F(2,58) = 1.03,
F(2,58) = 0.01,
p = .36
p = .99
F(3,174) = 55.63, F(3,174) = 13.65,
p < 0.001***
p < 0.001***
F(6,174) = 0.43,
F(6,174) = 0.44,
p = .86
p = .85
F(3,174) = 0.50,
F(3,174) = 1.50,
p = .68
p = .22
F(6,174) = 0.40,
F(6,174) = 0.30,
p = .88
p = .94
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REF
F(2,58) = 0.90,
p = .41
F(1,58) = 1.19,
p = .28
F(2,58) = 0.04,
p = .97
F(3,174) = 20.59,
p < .0001***
F(6,174) = 0.49,
p = .82
F(3,174) = 1.89,
p = .13
F(6,174) = 0.82,
p = .56

Table 3. Day 12, 4-hour delay. At 2.5 months of age, pre-tau expression, during the 4-hour delay,
there were no Group differences in errors made for any dependent measure. There was a
significant effect of Sex on WMI (p < .05). Also, there were significant trial effects for all errors
(ps < .0001).
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5 M Acquisition
Time
WMC
WMI
F (2,58) = 0.25,
F (2,58) = 0.82,
F (2,58) = 1.19,
p = .78
p = .44
p = .31
Group
F (1,58) = 6.03,
F (1,58) = 4.21,
F (1,58) = 5.10,
Sex
p = .02*
p = .04*
p = .03*
F (2,58) = 1.14,
F (2,58) = 1.18,
F (2,58) = 0.25,
p
=
.33
p
=
.31
p = .78
Group*Sex
F (9,522) = 6.33, F (9,522) = 1.05, F (9,522) = 6.65,
p = .40
Day
p < .0001***
p < .0001***
F (18,522) =1.13, F (18,522) = 1.25, F (18,522) = 0.79,
p = .32
p = .21
p = .71
Day*Group
F (9,522) = 0.72, F (9,522) = 1.05, F (9,522) = 0.22,
p = .69
p = .40
p = .99
Day*Sex
Day*Group F (18,522) = 0.94, F (18,522) = 1.11, F (18,522) = 0.78,
p = .52
p = .34
p = .72
*Sex
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REF
F (2,58) = 2.26,
p = .11
F (1,58) = 5.90,
p = .02*
F (2,58) = 0.21,
p = .81
F (9,522) = 6.60,
p < .0001***
F (18,522) = 1.77,
p = .03*
F (9,522) = 0.88,
p = .54
F (18,522) = 0.73,
p = .78

Table 4. Acquisition. At 5 months of age, 2.5 months post-tau expression, there was no Day
effect for WMC (p > .10); however, there were effects of Day for time, WMI, and REF (ps
> .0001). There were significant effects of Sex for all errors (ps < .05). There was also a
significant Day*Group effect where Veh-Controls initially made more REF errors but improved
with training, whereas Veh-TauP301L mice did not improve with additional training (p = .03).
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7.5 M Acquisition
Time
WMC
WMI
F (2,57) = 0.66,
F (2,57) = 1.02,
F (2,57) = 1.10,
p = .52
p = .37
p = .34
Group
F (1,57) = 0.18,
F (1,57) = 0.33,
F (1,57) = 0.05,
p = .67
p = .57
p = .82
Sex
F (2,57) = 0.27,
F (2,57) = 0.57,
F (2,57) = 0.38,
p
=.76
p
=
.57
p = .68
Group*Sex
F (9,513) = 9.72, F (9,513) = 4.08, F (9,513) = 9.25,
Day
p < .0001***
p < .0001***
p < .0001***
F (18,513) = 0.70, F (18,513) = 1.04, F (18,513) = 0.97,
p = .82
p = .42
p = .50
Day*Group
F (9,513) = 0.30, F (9,513) = 0.29,
F (9,513) = 0.41,
p = .97
p = .98
p = .93
Day*Sex
Day*Group F (18,513) = 1.24, F (18,513) = 1.19, F (18,513) = 0.93,
p = .22
p = .27
p = .54
*Sex
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REF
F (2,57) = 0.09,
p = .92
F (1,57) = 0.96,
p = .33
F (2,57) = 0.56,
p = .57
F (9,513) = 5.96,
p < .0001***
F (18,513) = 1.27,
p = .21
F (9,513) = 0.74,
p = .68
F (18,513) = 0.97,
p = .49

Table 5. Acquisition. At 7.5 months of age, 5 months post-tau expression, no effects of Group,
Sex, or Group*Sex interactions were observed on any error (ps > .10). There were significant
effects of day for all errors (ps < .0001).
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Group
Sex
Group*Sex
Trial
Trial*Group
Trial*Sex
Trial*Group
*Sex

Time
F(2,58) = 0.10,
p = .91
F(1,58) = 1.42,
p = .24
F(2,58) = 0.31,
p = .73
F(3,174) = 33.31,
p < .0001***
F(6,174) = 0.77,
p = .60
F(3,174) = 0.67,
p = .57
F(6,174) 0.72,
p = .63

5 M day 12 trials 1-4
WMC
WMI
F(2,58) = 0.78,
F(2,58) = 1.36,
p = .46
p = .26
F(1,58) = 1.66,
F(1,58) = 0.40,
p = .20
p = .53
F(2,58) = 1.60,
F(2,58) = 0.83,
p = .21
p = .44
F(3,174) = 42.53, F(3,174) = 12.57,
p < .0001***
p < .0001***
F(6,174) = 0.74,
F(6,174) = 1.08,
p = .62
p = .37
F(3,174) = 1.09,
F(3,174) = 0.30,
p = .36
p = .82
F(6,174) = 0.65,
F(6,174) = 0.36,
p = .69
p = .90
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REF
F(2,58) = 0.87,
p = .43
F(1,58) = 0.81,
p = .37
F(2,58) = 0.10,
p = .90
F(3,174) = 2.65,
p = .05*
F(6,174) = 2.11,
p = .05
F(3,174) = 2.24,
p = .09
F(6,174) = 0.82,
p = .56

Table 6. Day 12, 4-hour delay. At 5 months of age, 2.5 months post-tau expression, there were
no significant Group, Sex, or Group*Sex effects (ps > .10). There were effects of Trial for time
(p < .0001), WMC (p < .0001), WMI (ps < .0001), and REF errors (p = .05).
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Group
Sex
Group*Sex
Trial
Trial*Group
Trial*Sex
Trial*Group
*Sex

Time
F(2,58) = 1.86,
p = .16
F(1,58) = 2.63,
p = .11
F(2,58) = 0.28,
p = .75
F(3,174) = 31.15,
p < .0001***
F(6,174) = 1.71,
p = .12
F(3,174) = 0.96,
p = .41
F(6,174) = 0.21,
p = .97

5 M day 13 Trials 1-4
WMC
WMI
F(2,58) = 0.90,
F(2,58) = 5.49,
p = .41
p = 0.007**
F(1,58) = 1.50,
F(1,58) = 1.00,
p = .23
p = .32
F(2,58) = 0.01,
F(2,58) = 2.31,
p = .99
p = .11
F(3,174) = 38.91, F(3,174) = 10.76,
p < .0001***
p < .0001***
F(6,174) = 1.57,
F(6,174) = 1.96,
p = .16
p = .07
F(3,174) = 1.15,
F(3,174) = 0.20,
p = .33
p = .90
F(6,174) = 0.10,
F(6,174) = 0.56,
p > .99
p = .76
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REF
F(2,58) = 1.89,
p = .16
F(1,58) = 0.25,
p = .62
F(2,58) = 1.14,
p = .32
F(3,174) = 6.31,
p = .0004***
F(6,174) = 1.68,
p = .13
F(3,174) = 0.69,
p = .52
F(6,174) = 0.64,
p = .70

Table 7. Day 13, 6-hour delay. On day 13, at 5 months of age, Veh-TauP301L made more WMI
errors. No other effects of Group, Sex, or Group*Sex interactions were observed (ps > .05).
There were effects of Trial for time (p < .0001), WMC (p < .0001), WMI (p < .0001), and REF
errors (p = .0004).
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Group
Sex
Group*Sex
Trial
Trial*Group
Trial*Sex
Trial*Group
*Sex

Time
F(2,57) = 2.11,
p = .13
F(1,57) = 0.56,
p = .46
F(2,57) = 1.17,
p = .32
F(3,171) = 33.79,
p < .0001***
F(6,171) = 1.10,
p = .36
F(3,171) = 0.13,
p = .94
F(6,171) = 0.79,
p = .58

7.5 M day 12 trials 1-4
WMC
WMI
F(2,57) = 1.13,
F(2,57) = 2.09,
p = .33
p = .13
F(1,57) = 0.57,
F(1,57) = 0.04,
p = .45
p = .84
F(2,57) = 1.41,
F(2,57) = 1.55,
p = .25
p = .22
F(3,171) = 39.98, F(3,171) = 16.18,
p < .0001***
p < .0001***
F(6,171) = 1.00,
F(6,171) = 1.51,
p = .43
p = .18
F(3,171) = .48,
F(3,171) = 0.56,
p = .70
p = .64
F(6,171) = .75, p F(6,171) = 1.38, p
= .61
= .23
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REF
F(2,57) = 4.72,
p = .01*
F(1,57) = 0.08,
p =.77
F(2,57) = 1.50,
p = .23
F(3,171) = 4.33,
p = .006**
F(6,171) = 0.93,
p = .47
F(3,171) = 1.64,
p = .18
F(6,171) = 0.72, p
= .64

Table 8. Day 12, 6-hour delay. At 7.5 months of age, 5 months post-tau expression, VehTauP301L mice made more REF errors. No other effects of Group, Sex, or Group*Sex
interactions were observed (ps > .10) There were significant effects of Trial for time (p < .0001),
WMC (p < .0001), WMI, (p < .0001), and REF errors (p = .006).
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Group
Sex
Group*Sex
Trial
Trial*Group
Trial*Sex
Trial*Group
*Sex

Time
F(2,57) = 2.42,
p = .10
F(1,57) = 0.69,
p = .41
F(2,57) = 0.92,
p = .41
F(3,171) = 42.12,
p < .0001***
F(6,171) = 1.91,
p = .08
F(3,171) = 0.30,
p = .82
F(6,171) = 0.54,
p = .78

7.5 M day 13 Trials 1-4
WMC
WMI
F(2,57) = 1.99,
F(2,57) = 4.27,
p = .15
p = .02*
F(1,57) = 0.24,
F(1,57) = 0.03,
p = .63
p = .85
F(2,57) = 1.24,
F(2,57) = 0.12,
p = .30
p = .89
F(3,171) = 48.10, F(3,171) = 18.92,
p < .0001***
p < .0001***
F(6,171) = 1.82,
F(6,171) = 2.68,
p = .10
p = .02*
F(3,171) = .0.74,
F(3,171) = 0.25,
p = .53
p = .86
F(6,171) = 0.79,
F(6,171) = 0.26,
p = .58
p = .95
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REF
F(2,57) = 2.38,
p = .10
F(1,57) = 0.29,
p = .60
F(2,57) = 0.99,
p = .38
F(3,171) = 10.11,
p < .0001***
F(6,171) = 0.74,
p = .62
F(3,171) = 0.22,
p = .82
F(6,171) = 0.15,
p = .99

Table 9. Day 13, 6-hour delay. On Day 13, at 7.5 months of age, Veh-TauP301L mice made
more WMI errors as trials increased (p = .02). No effects of Group, Sex, or Sex*Group
interactions were observed for time, WMC, or REF errors (ps > .05).
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Group
Sex
Group*Sex
Day
Day*Group
Day*Sex
Day*Group
*Sex

Time
F (2,57) = 4.02,
p = .02*
F (1,57) = 1.56,
p = .22
F (2,57) = 1.10,
p = .33
F (1,57) = 0.00,
p = .99
F (2,57) = 0.04,
p = .96
F (1,57) = 0.45,
p = .50
F (2,57) = 0.07,
p = .93

5 and 7.5 M - Day 13; 6-hour delay
WMC
WMI
F (2,57) = 2.29,
F (2,57) = 7.96,
p = .07
p = .0009***
F (1,57) = 1.45,
F (1,57) = 0.00,
p = .23
p = .93
F (2,57) = 0.71,
F (2,57) = 0.83,
p = .50
p = .44
F (1,57) = 0.20,
F (1,57) = 0.30,
p = .66
p = .59
F (2,57) = 0.00,
F (2,57) = 0.26,
p > .99
p = .77
F (1,57) = 0.36,
F (2,57) = 0.90,
p = .55
p = .35
F (2,57) = 0.16,
F (2,57) = 0.62,
p = .85
p = .54
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REF
F (2,57) = 0.46,
p = .63
F (1,57) = 0.87,
p = .36
F (2,57) = 1.94,
p = .15
F (1,57) = 0.30,
p = .59
F (2,57) = 0.73,
p = .49
F (1,57) = 0.02,
p = .90
F (2,57) = 0.22,
p = .80

Table 10. Day 13, 6 hour delay at 5 and 7.5 months of age. A RMANOVA revealed that VehTauP301L mice took more time to find the platform and made more WMI errors at 5 and 7.5
months of age. No other effects of Group, Sex, or Group*Sex interactions were observed (ps
> .05).
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Time

Group
F (2,57) = 2.10,
p = .13

Visible Platform Test
Sex
F (1,57) = 0.80,
p = 0.37

61

Group*Sex
F (2,57) = 2.63,
p = .08

Table 11. Visible Platform Test. There were no differences in time to find the visible platform
(ps > .05) at the conclusion of behavioral testing.

